A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015
- PMID: 32171106
- DOI: 10.1016/j.ejca.2020.02.017
A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015
Abstract
Aim: To investigate the nationwide time trends in incidence and survival of oesophageal and gastric adenocarcinomas according to the Laurén classification (intestinal, diffuse and mixed type).
Methods: All patients diagnosed in the Netherlands with oesophageal or gastric adenocarcinoma between 1989 and 2015 were included. A syntax was developed to determine the histological subtype based on pathology reports as archived in the Dutch pathology registry. These reports were linked to individual data from the Netherlands Cancer Registry. Relative survival was used to assess survival.
Results: The histological subtype could be determined in 18.691 (84.1%) oesophageal and in 32.312 (83.5%) gastric adenocarcinomas. Among these, 79% were intestinal and 21% diffuse type in oesophageal cancers, compared to 55% intestinal and 44% diffuse type in gastric cancers. Relative median survival of intestinal type tumours was longer than that of diffuse type tumours, that is, 12.1 versus 9.4 months for oesophageal carcinomas, and 10.1 versus 7.6 months for gastric carcinomas, respectively. Between 1989 and 2015, the relative median survival of non-metastatic intestinal and diffuse type oesophageal adenocarcinoma improved from 12.0 to 30.0 months, and from 12.0 to 19.2 months, respectively. The same was true for intestinal type gastric carcinoma (from 22.8 to 27.6 months) but for diffuse type gastric carcinoma, the increase was less (from 16.8 to 18.0 months).
Conclusion: In this nationwide study, histological subtypes of oesophageal and gastric adenocarcinomas differed in incidence and survival times. These findings may call for a differentiated treatment approach.
Keywords: Adenocarcinoma; Diffuse type; Gastric neoplasms; Histology; Intestinal type; Laurén classification; Oesophageal neoplasms; Prognosis; Survival.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest statement None declared.
Similar articles
-
The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.Eur J Cancer. 2017 May;76:27-35. doi: 10.1016/j.ejca.2017.01.031. Epub 2017 Mar 3. Eur J Cancer. 2017. PMID: 28262585
-
The metastatic pattern of intestinal and diffuse type gastric carcinoma - A Dutch national cohort study.Cancer Epidemiol. 2020 Dec;69:101846. doi: 10.1016/j.canep.2020.101846. Epub 2020 Oct 27. Cancer Epidemiol. 2020. PMID: 33126042
-
Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females.Gut. 2009 Jan;58(1):16-23. doi: 10.1136/gut.2008.161331. Epub 2008 Oct 6. Gut. 2009. PMID: 18838486
-
Review article: oesophago-gastric adenocarcinoma -- an epidemiological perspective.Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:55-60; discussion 61-2. doi: 10.1111/j.1365-2036.2004.02133.x. Aliment Pharmacol Ther. 2004. PMID: 15456465 Review.
-
Time to Classify Tumours of the Stomach and the Kidneys According to Cell of Origin.Int J Mol Sci. 2021 Dec 13;22(24):13386. doi: 10.3390/ijms222413386. Int J Mol Sci. 2021. PMID: 34948181 Free PMC article. Review.
Cited by
-
The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma.Ann Surg Oncol. 2022 Jun;29(6):3658-3666. doi: 10.1245/s10434-022-11336-3. Epub 2022 Jan 29. Ann Surg Oncol. 2022. PMID: 35094189
-
Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit.Gastric Cancer. 2022 Jan;25(1):22-32. doi: 10.1007/s10120-021-01225-1. Epub 2021 Aug 7. Gastric Cancer. 2022. PMID: 34365540 Free PMC article.
-
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention.Nat Rev Clin Oncol. 2023 May;20(5):338-349. doi: 10.1038/s41571-023-00747-0. Epub 2023 Mar 23. Nat Rev Clin Oncol. 2023. PMID: 36959359 Review.
-
A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands.J Cancer Res Clin Oncol. 2023 Nov;149(14):13323-13330. doi: 10.1007/s00432-023-05111-4. Epub 2023 Jul 24. J Cancer Res Clin Oncol. 2023. PMID: 37486395 Free PMC article.
-
Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma.Curr Oncol. 2024 Dec 4;31(12):7770-7786. doi: 10.3390/curroncol31120572. Curr Oncol. 2024. PMID: 39727695 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous